Connor, Clark & Lunn Investment Management (CC&L)’s Adamas Pharmaceuticals, Inc. ADMS Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q1 | – | Sell |
-24,595
| Closed | -$106K | – | 1139 |
|
|
2020
Q4 | $106K | Buy |
24,595
+8,165
| +50% | +$35.2K | ﹤0.01% | 857 |
|
|
2020
Q3 | $68K | Buy |
16,430
+3,176
| +24% | +$13.1K | ﹤0.01% | 889 |
|
|
2020
Q2 | $34K | Sell |
13,254
-30,712
| -70% | -$78.8K | ﹤0.01% | 990 |
|
|
2020
Q1 | $127K | Buy |
43,966
+20,066
| +84% | +$58K | ﹤0.01% | 911 |
|
|
2019
Q4 | $91K | Buy |
+23,900
| New | +$91K | ﹤0.01% | 882 |
|
|
2016
Q1 | – | Sell |
-13,600
| Closed | -$385K | – | 927 |
|
|
2015
Q4 | $385K | Buy |
13,600
+3,000
| +28% | +$84.9K | ﹤0.01% | 591 |
|
|
2015
Q3 | $177K | Sell |
10,600
-400
| -4% | -$6.68K | ﹤0.01% | 652 |
|
|
2015
Q2 | $288K | Hold |
11,000
| – | – | ﹤0.01% | 503 |
|
|
2015
Q1 | $192K | Buy |
+11,000
| New | +$192K | ﹤0.01% | 506 |
|